To develop and bring to market innovative technologies for the national and international medical community that will positively impact those who have been infected with viral diseases and introduce cost effective medical solutions for improving the quality of life of their patients.
ABOUT DEEP BLUE:
Deep Blue, Inc. is an organization that is bringing to market a patent-pending treatment, (Application Number 11/208,402), for HIV /AIDS and other viral infectious diseases
. Deep Blue’s protocols and technology have been in development for over 9 years. In April 2005, Deep Blue Inc. was granted the only FDA Non-significant Risk Status for the treatment of AIDS and Hepatitis C using class “A” medical devices.The FDA Stage-II single-site study has been approved to conduct human trials and is scheduled to be completed by January 30, 2007. Deep Blue, Inc. will complete their multi-site trials at several leading research hospitals in the first quarter of 2007.
All investor inquiries should be directed via email to email@example.com
COMPANY NEWS AND PRESS RELEASES
11/21/2006 - Deep Blue Announces Management Decision
(A symbol and cusip number change.)
11/20/2006 - Deep Blue, Inc. Explains Equity Investment
11/17/2006 - Deep Blue, Inc. Orders NOBO List
(..and OBO list.)
11/16/2006 - Deep Blue, Inc. Receives Letter of Interest for Initial Funding
10/31/2006 - Deep Blue, Inc. Reveals North American Market Potential
In Certificate Form: 35,000,000
Free Trading Shares: 32,593,852
45 Million shares were retired to the treasury October 2006.
This board will not tolerate any nonsense. Personal attacks are expressly forbidden.